The role of ancillary ligand substituents in the biological activity of triruthenium-NO complexes

A novel triruthenium nitrosyl bearing a quinolinic ligand: a comparison of its spectroscopic behavior with its pyridine analogues

“…The electronic spectrum of the compound [Ru 3 O(CH 3 COO) 6 -(iq) 2 NO]PF 6 displayed bands at 701 nm (842 L mol À1 cm À1 ), 549 nm (1514 L mol À1 cm À1 ), and 458 nm (1703 L mol À1 cm À1 ), which are ascribed to IC and two CLCT transitions, respectively (Table 1). 12,23,24,36,37 A desirable type of behavior of these compounds is their ability to generate NO upon light irradiation, as shown in Fig. 2.…”

“…To compare the spectroscopic data of the target compound with the data of the pyridine analogues, literature data were used. 12,23,24,37 The band maximum used in the attempts to correlate the data from the electronic spectra was obtained using the spectral deconvolution method with the aid of Originr 2020 software.…”

“…2,3,[5][6][7] Therefore, they have numerous potential applications ranging from the construction of storage devices for energy and information [8][9][10] to the development of metallodrugs. Only a few studies on this last topic are available, including anticancer and trypanocidal activities [11][12][13][14] and their interactions with HSA (human serum albumin) 15 and DNA. 16 The ability of these compounds to perform photoinduced processes like electron-transfer reactions [17][18][19] or the photoinduced release of active molecules is relevant to this work.…”

“…[25][26][27] In this context, ruthenium complexes have shown good results. [28][29][30][31][32][33][34][35] Our group has demonstrated that triruthenium acetate compounds are particularly good candidates for melanoma treatment 12,36 and vasodilation. 37 Variations in the ancillary ligands have been shown to modulate the electronic properties of trinuclear compounds, 6,12,20,38,39 as in the case of mononuclear compounds.…”

“…[28][29][30][31][32][33][34][35] Our group has demonstrated that triruthenium acetate compounds are particularly good candidates for melanoma treatment 12,36 and vasodilation. 37 Variations in the ancillary ligands have been shown to modulate the electronic properties of trinuclear compounds, 6,12,20,38,39 as in the case of mononuclear compounds. 40 In this scenario, we aim to broaden the knowledge on triruthenium nitrosyl compounds by introducing data concerning a novel compound, [Ru 3 O(CH 3 COO) 6 (iq) 2 NO]PF 6 , which bears the azanaphthalene ligand iq = isoquinoline (Fig.…”